By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Evotec today said that it has completed its acquisition of DeveloGen, a German biopharmaceutical discovery and development firm, in a deal worth up to €14 million ($17.9 million).

Hamburg, Germany-based Evotec inked the agreement to acquire DeveloGen in July. It said that as of closing of the deal, the sellers of 99.3 percent of DeveloGen's shares had transferred their shares to Evotec.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.